MSK hematologic oncologist Heather Landau

Heather J. Landau, MD

Hematologic Oncologist

Clinical Expertise

Hematologic Malignancies; Plasma Cell Dyscrasias, Including Multiple Myeloma, Light Chain Amyloidosis, and Plasmacytomas

New Patient Appointments

Scheduling a visit is easy. Click below or call us to get started.

Accepted Insurance Providers

Dr. Landau accepts the following list of insurance providers. Select your insurance provider to see more details.

Contact and Location

Locations map

Find a Convenient Location

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offers many services, including screening, chemotherapy, and medical testing.

About Me


MD, Upstate Medical University


Internal Medicine - University of Colorado Health Sciences Center


Hematology/Oncology - Memorial Sloan Kettering Cancer Center

Board Certifications

Internal Medicine; Medical Oncology; Hematology

I am a board-certified oncologist and hematologist, and work as part of a multidisciplinary team caring for patients with hematologic disorders. I have a special interest and expertise in treating patients with disorders that arise in white blood cells called plasma cells, including multiple myeloma and light chain (AL) amyloidosis.

My research focuses on new treatment approaches for plasma cell disorders. Along with colleagues here, I am testing targeted therapies, immunomodulatory agents, and stem cell transplantation to arrive at more-effective and less-toxic regimens for these diseases.

Very effective novel agents have recently become available for plasma cell disorders, but it is not clear if these are more effective than stem cell transplantation for patients early in the course of their disease. To help answer that question, I am co-leading a study comparing the effectiveness of an immunomodulatory agent (lenalidomide) with that of high-dose therapy and stem cell transplantation. I am also leading a trial to determine the most effective post-stem cell transplant therapy. As the principal investigator of an ongoing trial using a risk-adapted approach to stem cell transplant followed by novel agents in AL amyloidosis, I have had the opportunity to present exciting results demonstrating significant activity and low toxicity with this approach.

For patients whose plasma cell disorder has relapsed, I am investigating novel agents alone and in combinations. Some patients with multiple myeloma and plasma cell disorders do poorly despite treatment. I am collaborating with colleagues here in efforts to develop safer and more-effective donor-derived (allogeneic) hematopoietic stem cell transplantation options using T-cell-depleted grafts, a strategy pioneered at Memorial Sloan Kettering. In order to improve accessibility to treatment and the quality of life of our patients, I am also helping to develop outpatient transplant strategies using state-of-the-art technology (Tele-Health monitoring).

I have also enjoyed mentoring students from the college level through the post-graduate level.


Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

Clinical Trials

Research and Publications

Publications on PubMed

Visit PubMed for a full listing of Dr. Landau’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.